

# Patrice Dubreuil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7733930/publications.pdf>

Version: 2024-02-01

161  
papers

9,909  
citations

20817

60  
h-index

39675

94  
g-index

166  
all docs

166  
docs citations

166  
times ranked

9328  
citing authors

#	ARTICLE	IF	CITATIONS
1	TET2 regulates immune tolerance in chronically activated mast cells. JCI Insight, 2022, 7, .	5.0	4
2	Criteria for the Regression of Pediatric Mastocytosis: A Long-Term Follow-Up. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1695-1704.e5.	3.8	10
3	GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness. Blood, 2021, 138, 1590-1602.	1.4	4
4	The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. Blood, 2021, 138, 2396-2407.	1.4	5
5	Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 5-14.	1.7	133
6	Effects of Chronic Masitinib Treatment in APP <sup>swe</sup> /PSEN1 <sup>dE9</sup> Transgenic Mice Modeling Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 76, 1339-1345.	2.6	26
7	Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. Allergology International, 2019, 68, 119-121.	3.3	2
8	Neuroinflammatory disorders and mastocytosis: A possible association?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2878-2881.e1.	3.8	2
9	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British Journal of Haematology, 2019, 187, 488-501.	2.5	30
10	Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2387-2395.e3.	3.8	42
11	KIT as a therapeutic target for non-oncological diseases. , 2019, 197, 11-37.		14
12	Recent advances in the understanding and therapeutic management of mastocytosis. F1000Research, 2019, 8, 1961.	1.6	12
13	The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells. Frontiers in Immunology, 2018, 9, 364.	4.8	26
14	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet, The, 2017, 389, 612-620.	13.7	95
15	Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. Nature Communications, 2017, 8, 1420.	12.8	18
16	Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight, 2017, 2, .	5.0	68
17	Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. Journal of Clinical Investigation, 2017, 127, 2310-2325.	8.2	26
18	Adult T cell leukemia aggressiveness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. Oncotarget, 2017, 8, 52256-52268.	1.8	20

#	ARTICLE	IF	CITATIONS
19	An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 51163-51173.	1.8	15
20	Trans-inhibition of activation and proliferation signals by Fc receptors in mast cells and basophils. <i>Science Signaling</i> , 2016, 9, ra126.	3.6	31
21	Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. <i>Clinical and Experimental Allergy</i> , 2016, 46, 133-141.	2.9	8
22	Familial hematological malignancies: new IDH2 mutation. <i>Annals of Hematology</i> , 2016, 95, 1943-1947.	1.8	7
23	Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2016, 13, 177.	7.2	116
24	Mastocytosis among elderly patients. <i>Medicine (United States)</i> , 2016, 95, e3901.	1.0	6
25	Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 416-420.	5.7	4
26	Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016, 374, 2605-2606.	27.0	54
27	Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. <i>Molecular Psychiatry</i> , 2016, 21, 1511-1516.	7.9	64
28	Lineage-specific enhancers activate self-renewal genes in macrophages and embryonic stem cells. <i>Science</i> , 2016, 351, aad5510.	12.6	194
29	Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 885-891.e1.	1.2	30
30	DNMT3A R882H mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. <i>Leukemia</i> , 2016, 30, 1388-1398.	7.2	67
31	Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2016, 11, e0156063.	2.5	35
32	Mast cell sarcoma: new cases and literature review. <i>Oncotarget</i> , 2016, 7, 66299-66309.	1.8	46
33	Screening of candidate G-quadruplex ligands for the human <i>c-KIT</i> promotorial region and their effects in multiple <i>in-vitro</i> models. <i>Oncotarget</i> , 2016, 7, 21658-21675.	1.8	35
34	Abstract 4868: Tyrosine kinase-dependent modulation of tumor infiltrating immune cells in melanoma. , 2016, , .		0
35	Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. <i>Blood</i> , 2015, 126, 1009-1016.	1.4	116
36	Recurrent TET2 mutations in adult T cell leukemia (ATL) and identification of a Single Nucleotide polymorphism in TET2 region predisposing to ATL development. <i>Retrovirology</i> , 2015, 12, .	2.0	0

#	ARTICLE	IF	CITATIONS
37	Isolated flushes without permanent, fixed or other skin lesions in patients with systemic mastocytosis: a case series of 9 patients. <i>European Journal of Dermatology</i> , 2015, 25, 182-184.	0.6	0
38	Activation of <sc>KIT</sc> modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 764-774.	5.7	5
39	Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors. <i>PLoS ONE</i> , 2015, 10, e0142450.	2.5	10
40	Paediatric mastocytosis: a systematic review of 1747 cases. <i>British Journal of Dermatology</i> , 2015, 172, 642-651.	1.5	143
41	A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. <i>Annals of Oncology</i> , 2015, 26, 1194-1200.	1.2	78
42	KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. <i>Leukemia</i> , 2015, 29, 1223-1232.	7.2	229
43	Neuroprotective effect of masitinib in rats with postischemic stroke. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 79-86.	3.0	25
44	Molecular basis of mast cell disease. <i>Molecular Immunology</i> , 2015, 63, 55-60.	2.2	19
45	Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3526-3526.	1.6	4
46	Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4027-4027.	1.6	1
47	Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report. <i>Biomedical Papers of the Medical Faculty of the University Palacký&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2015, 159, 695-697.	0.6	8
48	Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1070-1070.	1.6	0
49	Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3993-3993.	1.4	0
50	ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases. <i>PLoS ONE</i> , 2014, 9, e85362.	2.5	65
51	Hotspot Mutations in KIT Receptor Differentially Modulate Its Allosterically Coupled Conformational Dynamics: Impact on Activation and Drug Sensitivity. <i>PLoS Computational Biology</i> , 2014, 10, e1003749.	3.2	27
52	Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial. <i>Annals of Oncology</i> , 2014, 25, 1762-1769.	1.2	65
53	Absence of circulating mast cell precursors in paediatric mastocytosis: could it reflect a different pathophysiology between adults and children with mastocytosis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 967-971.	2.4	3
54	Characterization of S628N. <i>JAMA Dermatology</i> , 2014, 150, 1345.	4.1	6

#	ARTICLE	IF	CITATIONS
55	Molecular Defects in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 239-262.	1.9	67
56	KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570. <i>Oncogene</i> , 2014, 33, 872-881.	5.9	23
57	Leukocyte telomere length in mastocytosis: Correlations with depression and perceived stress. <i>Brain, Behavior, and Immunity</i> , 2014, 35, 51-57.	4.1	25
58	SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. <i>Haematologica</i> , 2014, 99, 830-835.	3.5	55
59	A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. <i>Blood</i> , 2014, 124, 111-120.	1.4	80
60	Treatment of Advanced Systemic Mastocytosis with PKC412: The French Compassionate Use Programme Experience and Historical Comparison. <i>Blood</i> , 2014, 124, 3193-3193.	1.4	3
61	Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2013, 73, 3499-3510.	0.9	277
62	Gastrointestinal manifestations in mastocytosis: A study of 83 patients. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 866-873.e3.	2.9	66
63	Imatinib Mesylate in the Treatment of Diffuse Cutaneous Mastocytosis. <i>Journal of Pediatrics</i> , 2013, 162, 205-207.	1.8	30
64	Relocalization of KIT D816V to Cell Surface After Dasatinib Treatment: Potential Clinical Implications. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 62-69.	0.4	8
65	Mast cell leukemia. <i>Blood</i> , 2013, 121, 1285-1295.	1.4	153
66	Mast Cell Sarcoma: A Rare and Aggressive Entity—Report of Two Cases and Review of the Literature. <i>Journal of Clinical Oncology</i> , 2013, 31, e90-e97.	1.6	43
67	Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. <i>British Journal of Haematology</i> , 2013, 161, 434-442.	2.5	9
68	Nectin-3 (CD113) Interacts with Nectin-2 (CD112) to Promote Lymphocyte Transendothelial Migration. <i>PLoS ONE</i> , 2013, 8, e77424.	2.5	25
69	Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket. <i>PLoS ONE</i> , 2013, 8, e60961.	2.5	19
70	In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. <i>Blood</i> , 2012, 120, 4846-4849.	1.4	89
71	Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. <i>Veterinary and Comparative Oncology</i> , 2012, 10, 143-154.	1.8	32
72	Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. <i>BMC Neurology</i> , 2012, 12, 36.	1.8	104

#	ARTICLE	IF	CITATIONS
73	Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. <i>European Journal of Medicinal Chemistry</i> , 2012, 47, 239-254.	5.5	70
74	Mast cell leukemia: identification of a new <i>c-Kit</i> mutation, dup(501â€502), and response to masitinib, a <i>c-Kit</i> tyrosine kinase inhibitor. <i>European Journal of Haematology</i> , 2012, 89, 47-52.	2.2	45
75	Masitinib as a chemosensitizer of canine tumor cell lines: A proof of concept study. <i>Veterinary Journal</i> , 2012, 191, 131-134.	1.7	23
76	Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 16.	6.2	128
77	Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. <i>Veterinary Dermatology</i> , 2011, 22, 554-564.	1.2	19
78	Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. <i>Oncogene</i> , 2011, 30, 3862-3874.	5.9	52
79	Mechanisms of STAT Protein Activation by Oncogenic KIT Mutants in Neoplastic Mast Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 5956-5966.	3.4	58
80	Blood CD34 <sup>hi</sup> c-Kit <sup>+</sup> cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor. <i>Blood</i> , 2011, 118, 5246-5249.	1.4	25
81	Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. <i>Blood</i> , 2010, 116, 1114-1123.	1.4	52
82	Gastrointestinal involvement and manifestations in systemic mastocytosis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1247-1253.	1.9	88
83	Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study. <i>American Journal of Hematology</i> , 2010, 85, 921-925.	4.1	98
84	Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. <i>Leukemia</i> , 2010, 24, 642-645.	7.2	58
85	FES kinases are required for oncogenic FLT3 signaling. <i>Leukemia</i> , 2010, 24, 721-728.	7.2	28
86	Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model. <i>PLoS ONE</i> , 2010, 5, e9430.	2.5	62
87	Systemic mastocytosis and bone involvement in a cohort of 75 patients. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1838-1841.	0.9	135
88	Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. <i>American Journal of Veterinary Research</i> , 2010, 71, 1354-1361.	0.6	67
89	Pediatric Mastocytosis Is a Clonal Disease Associated with D816V and Other Activating c-KIT Mutations. <i>Journal of Investigative Dermatology</i> , 2010, 130, 804-815.	0.7	329
90	FES kinase participates in KIT-ligand induced chemotaxis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 393, 174-178.	2.1	6

#	ARTICLE	IF	CITATIONS
91	Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients. <i>Blood</i> , 2010, 116, 1982-1982.	1.4	12
92	Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT. <i>PLoS ONE</i> , 2009, 4, e7258.	2.5	346
93	Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. <i>Arthritis Research and Therapy</i> , 2009, 11, R95.	3.5	60
94	Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. <i>Journal of Veterinary Internal Medicine</i> , 2008, 22, 1301-1309.	1.6	244
95	Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors. <i>Molecular Cancer Research</i> , 2008, 6, 1137-1145.	3.4	147
96	Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset. <i>PLoS ONE</i> , 2008, 3, e1906.	2.5	84
97	Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis. <i>PLoS ONE</i> , 2008, 3, e2266.	2.5	135
98	The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. <i>Blood</i> , 2007, 110, 2593-2599.	1.4	44
99	Desmoid-Type Fibromatosis. <i>Journal of Neurosurgery</i> , 2007, 107, 473-475.	1.6	3
100	Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. <i>Oncogene</i> , 2007, 26, 298-307.	5.9	81
101	Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. <i>Oncogene</i> , 2007, 26, 3904-3908.	5.9	25
102	AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. <i>Leukemia</i> , 2007, 21, 877-885.	7.2	31
103	Human erythroleukemia: is the two-hit model of mouse leukemogenesis valid in human disease?. <i>Leukemia</i> , 2007, 21, 2212-2214.	7.2	1
104	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. <i>BMC Cancer</i> , 2007, 7, 73.	2.6	134
105	The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. <i>FEBS Letters</i> , 2006, 580, 2609-2614.	2.8	31
106	Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. <i>Blood</i> , 2006, 108, 1065-1072.	1.4	62
107	Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. <i>Oncology Reports</i> , 2006, 16, 97.	2.6	9
108	Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases. <i>Leukemia</i> , 2006, 20, 1634-1636.	7.2	64

#	ARTICLE	IF	CITATIONS
109	F.115. Mastocytosis in Mice Expressing Human Kit Receptor with the Activating Asp816val Mutation. <i>Clinical Immunology</i> , 2006, 119, S91.	3.2	0
110	Response of a KIT-Positive Extra-Abdominal Fibromatosis to Imatinib Mesylate and KIT Genetic Analysis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 562-563.	6.3	27
111	Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. <i>Cancer Cell</i> , 2005, 8, 467-478.	16.8	48
112	Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome. <i>Cancer Research</i> , 2005, 65, 7231-7240.	0.9	37
113	NACA is a positive regulator of human erythroid-cell differentiation. <i>Journal of Cell Science</i> , 2005, 118, 1595-1605.	2.0	17
114	Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. <i>Journal of Experimental Medicine</i> , 2005, 202, 1635-1641.	8.5	81
115	Nectin-4, a New Serological Breast Cancer Marker, Is a Substrate for Tumor Necrosis Factor- $\alpha$ -converting Enzyme (TACE)/ADAM-17. <i>Journal of Biological Chemistry</i> , 2005, 280, 19543-19550.	3.4	136
116	Molecular Modeling of Wild-Type and D816V c-Kit Inhibition Based on ATP-Competitive Binding of Ellipticine Derivatives to Tyrosine Kinases. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 6194-6201.	6.4	34
117	PICK-1: A scaffold protein that interacts with Nectins and JAMs at cell junctions. <i>FEBS Letters</i> , 2005, 579, 2243-2249.	2.8	35
118	DNAM-1 and PVR Regulate Monocyte Migration through Endothelial Junctions. <i>Journal of Experimental Medicine</i> , 2004, 199, 1331-1341.	8.5	236
119	Suppressor of Cytokine Signaling 6 Associates with KIT and Regulates KIT Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2004, 279, 12249-12259.	3.4	71
120	Efficacy and Safety of Cladribine in Adult Systemic Mastocytosis : A French Multicenter Study of 33 Patients.. <i>Blood</i> , 2004, 104, 661-661.	1.4	12
121	Functional characterization of human CD34+ cells that express low or high levels of the membrane antigen CD111 (nectin 1). <i>Leukemia</i> , 2003, 17, 1137-1145.	7.2	8
122	Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. <i>Oncogene</i> , 2003, 22, 660-664.	5.9	179
123	Signal transduction by several KIT juxtamembrane domain mutations. <i>Oncogene</i> , 2003, 22, 4710-4722.	5.9	65
124	Prominent Role of the Ig-like V Domain intran-Interactions of Nectins. <i>Journal of Biological Chemistry</i> , 2002, 277, 27006-27013.	3.4	115
125	Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC $\beta$ 1: implication in stem cell factor radioprotective effect. <i>Blood</i> , 2002, 100, 1294-1301.	1.4	46
126	The tumor suppressor activity of SOCS-1. <i>Oncogene</i> , 2002, 21, 4351-4362.	5.9	123



#	ARTICLE	IF	CITATIONS
127	«Le piégeage de gènes» : un outil efficace de la génomique fonctionnelle. <i>Medecine/Sciences</i> , 2002, 18, 667-670.	0,2	0
128	Comparison of Murine and Human Nectin1 Binding to Herpes Simplex Virus Glycoprotein D (gD) Reveals a Weak Interaction of Murine Nectin1 to gD and a gD-Dependent Pathway of Entry. <i>Virology</i> , 2001, 282, 256-266.	2.4	18
129	Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase C $\beta$ . <i>Oncogene</i> , 2001, 20, 6752-6763.	5.9	21
130	Nectin4/PRR4, a New Afadin-associated Member of the Nectin Family That Trans-interacts with Nectin1/PRR1 through V Domain Interaction. <i>Journal of Biological Chemistry</i> , 2001, 276, 43205-43215.	3.4	263
131	Novel, Soluble Isoform of the Herpes Simplex Virus (HSV) Receptor Nectin1 (or PRR1-HlgR-HveC) Modulates Positively and Negatively Susceptibility to HSV Infection. <i>Journal of Virology</i> , 2001, 75, 5684-5691.	3.4	46
132	Suppressor of Cytokine Signaling 1 Interacts with the Macrophage Colony-stimulating Factor Receptor and Negatively Regulates Its Proliferation Signal. <i>Journal of Biological Chemistry</i> , 2001, 276, 22133-22139.	3.4	42
133	Chimeric Nectin1-Poliovirus Receptor Molecules Identify a Nectin1 Region Functional in Herpes Simplex Virus Entry. <i>Journal of Virology</i> , 2001, 75, 7987-7994.	3.4	31
134	Capture of cytokine-responsive genes (NACA and RBM3) using a gene trap approach. <i>Blood</i> , 2000, 95, 3750-3757.	1.4	17
135	The murine homolog of human Nectin1delta serves as a species nonspecific mediator for entry of human and animal alpha herpesviruses in a pathway independent of a detectable binding to gD. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 4867-4872.	7.1	60
136	Nectin2 $\pm$ (PRR2 $\pm$ or HveB) and Nectin2 $\prime$ Are Low-Efficiency Mediators for Entry of Herpes Simplex Virus Mutants Carrying the Leu25Pro Substitution in Glycoprotein D. <i>Journal of Virology</i> , 2000, 74, 1267-1274.	3.4	126
137	Cell-to-Cell Spread of Wild-Type Herpes Simplex Virus Type 1, but Not of Syncytial Strains, Is Mediated by the Immunoglobulin-Like Receptors That Mediate Virion Entry, Nectin1 (PRR1/HveC/HlgR) and Nectin2 (PRR2/HveB). <i>Journal of Virology</i> , 2000, 74, 3909-3917.	3.4	106
138	Human nectin3/PRR3: a novel member of the PVR/PRR/nectin family that interacts with afadin. <i>Gene</i> , 2000, 255, 347-355.	2.2	68
139	Capture of cytokine-responsive genes (NACA and RBM3) using a gene trap approach. <i>Blood</i> , 2000, 95, 3750-3757.	1.4	9
140	SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. <i>Leukemia</i> , 1999, 13, 1374-1382.	7.2	69
141	Socs1 binds to multiple signalling proteins and suppresses Steel factor-dependent proliferation. <i>EMBO Journal</i> , 1999, 18, 904-915.	7.8	192
142	Specific and common activities of the FLT3 and KIT tyrosine kinase receptors revealed by the use of cultured mast cells. <i>Leukemia</i> , 1998, 12, 1089-1098.	7.2	4
143	The V domain of herpesvirus Ig-like receptor (HlgR) contains a major functional region in herpes simplex virus-1 entry into cells and interacts physically with the viral glycoprotein D. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 15700-15705.	7.1	117
144	The Human Poliovirus Receptor Related 2 Protein Is a New Hematopoietic/Endothelial Homophilic Adhesion Molecule. <i>Blood</i> , 1998, 92, 4602-4611.	1.4	159

#	ARTICLE	IF	CITATIONS
145	The Human Poliovirus Receptor Related 2 Protein Is a New Hematopoietic/Endothelial Homophilic Adhesion Molecule. <i>Blood</i> , 1998, 92, 4602-4611.	1.4	12
146	Expression and Signal Transduction of the FLT3 Tyrosine Kinase Receptor. <i>Acta Haematologica</i> , 1996, 95, 218-223.	1.4	90
147	Phosphatidylinositol-3 Kinase Is Not Required for Mitogenesis or Internalization of the Flt3/Flk2 Receptor Tyrosine Kinase. <i>Journal of Biological Chemistry</i> , 1996, 271, 20075-20081.	3.4	32
148	Complementary DNA characterization and chromosomal localization of a human gene related to the poliovirus receptor-encoding gene. <i>Gene</i> , 1995, 155, 261-265.	2.2	156
149	The human PRR2 gene, related to the human poliovirus receptor gene (PVR), is the true homolog of the murine MPH gene. <i>Gene</i> , 1995, 159, 267-272.	2.2	179
150	Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. <i>Nature</i> , 1994, 368, 643-648.	27.8	423
151	The c-fms gene complements the mitogenic defect in mast cells derived from mutant W mice but not mi (microphthalmia) mice.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 2341-2345.	7.1	67
152	The Mouse W/c-kit Locus.. <i>Annals of the New York Academy of Sciences</i> , 1990, 599, 58-65.	3.8	31
153	Anti-interleukin 2 receptor monoclonal antibodies. Respective role of epitope mapping and monoclonal antibody-receptor interactions in their antagonist effects on interleukin 2-dependent T cell growth. <i>European Journal of Immunology</i> , 1986, 16, 611-616.	2.9	57
154	Anti-CD2 (sheep red blood cell receptor) monoclonal antibodies and T cell activation I. Pairs of anti-T11.1 and T11.2 (CD2 subgroups) are strongly mitogenic for T cells in presence of 12-O-tetradecanoylphorbol 13-acetate. <i>European Journal of Immunology</i> , 1986, 16, 1063-1068.	2.9	81
155	Two distinct TL-like molecular subsets defined by monoclonal antibodies on the surface of human thymocytes with different expression on leukemia lines. <i>Immunogenetics</i> , 1984, 20, 253-264.	2.4	66
156	Transformation of LMTK? cells with purified HLA class I genes. <i>Immunogenetics</i> , 1983, 18, 65-77.	2.4	27
157	Mouse monoclonal anti-Ia antibodies recognize cross-reacting determinants expressed on distinct subsets of human Ia-like cell-surface molecules. <i>Molecular Immunology</i> , 1983, 20, 511-520.	2.2	2
158	Identification on I-Ak molecules of a functional site recognized by proliferating T-lymphocytes. <i>Immunogenetics</i> , 1982, 16, 407-424.	2.4	9
159	Affinity and Inhibitory Capacity of T-Cell Proliferation of Monoclonal Anti-Ia Antibodies. <i>Scandinavian Journal of Immunology</i> , 1982, 16, 233-241.	2.7	8
160	Cell surface fixation of alloantigen bearing plasma vesicles in the presence of polyethylene glycol. <i>Journal of Immunological Methods</i> , 1981, 44, 285-299.	1.4	1
161	KLH-specific, I-E/C-restricted clones of proliferating T lymphocytes. <i>Immunogenetics</i> , 1981, 14, 469-479.	2.4	5